Phòng ngừa sơ cấp

Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention Approach

By MedXY 09/15/2026

This review synthesizes emerging evidence from the PROACT trials on genotype-first identification of subclinical coronary atherosclerosis using polygenic risk scores (PRS), highlighting feasibility, engagement, and high prevalence of silent plaque with implications for targeted early intervention.

Cardiology news

Evolocumab Significantly Reduces Mortality in High-Risk Patients Without Prior Heart Attack or Stroke: Insights from the VESALIUS-CV Trial

By MedXY 09/08/2026

The VESALIUS-CV trial demonstrates that evolocumab lowers all-cause and cardiovascular mortality in patients with high cardiovascular risk but no prior myocardial infarction or stroke, highlighting its survival benefits in primary prevention.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

By MedXY 03/12/2026

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% relative risk reduction.

Diabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

By MedXY 01/13/2026

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.